CARI Therapeutics intends to transform opioid use disorder (OUD) treatment with a bio-sensor based continuous monitoring system that reduces relapse rates and saves lives.

The CARI system starts with a single, tiny micro-biosensor that can measure opioid consumption and is implanted under the skin by a healthcare provider. The microscale biosensor module is small enough that it can be directly injected under the skin using only a 16-gauge needle. The injected device communicates with a sensor in a wearable band, which is similar to a fitbit device and facilitates communication between a smartphone and the implant. Similar to the function that continuous glucose monitors fulfill in treating diabetics, patients who are diagnosed with an opioid use disorder (OUD) can be prescribed the CARI continuous opioid monitoring solution, which sends biosensor data to treatment providers with the goal of conducting just-in-time adaptive interventions (JITAI) to modify their behavior. Patients will...
CARI Therapeutics intends to transform opioid use disorder (OUD) treatment with a bio-sensor based continuous monitoring system that reduces relapse rates and saves lives.

The CARI system starts with a single, tiny micro-biosensor that can measure opioid consumption and is implanted under the skin by a healthcare provider. The microscale biosensor module is small enough that it can be directly injected under the skin using only a 16-gauge needle. The injected device communicates with a sensor in a wearable band, which is similar to a fitbit device and facilitates communication between a smartphone and the implant. Similar to the function that continuous glucose monitors fulfill in treating diabetics, patients who are diagnosed with an opioid use disorder (OUD) can be prescribed the CARI continuous opioid monitoring solution, which sends biosensor data to treatment providers with the goal of conducting just-in-time adaptive interventions (JITAI) to modify their behavior. Patients will have the option to alert others, including loved ones and members of the treatment team, to apply treatment or intervene if needed.

Currently, OUD treatment requires disruptive and cumbersome bio-specimen monitoring procedures, some of which provide only temporal, incomplete data sets, e.g., their detection capability is limited to a certain time window after potential drug intake. Our proposed solution removes many of the obstacles associated with conventional bio-specimen monitoring procedures that render them distressing, inconvenient and difficult. The obstacles include the requirement to travel to specific locations to provide samples, the embarrassment of observed sample collection, the difficulty of providing a urine sample on demand that many patients report, and the hassle of chain-of-custody sample monitoring. In addition to providing continuous monitoring that generates more complete information than point-of-care intermittent time points of use, our minimally invasive device will save much time and hassle in comparison to current methods.

We have completed 3 I-Corps programs which were instrumental in helping us identify an initial niche market that will serve as a beachhead into the broader market: licensed professionals, such as doctors, nurses, and lawyers, who are on probation and at risk of losing their licenses if they do not remain sober. These customers are highly motivated to seek treatment and highly receptive to an implantable biosensor.
More information

Employees

Patrik Schmidle
Admin
Patrik Schmidle CEO I am an entrepreneur, business leader, coach and mentor with a passion for guiding people and companies to achieve extraordinary results.
Rajesh Seenivasan
Admin
Rajesh Seenivasan
Laurie Russell
Admin
Laurie Russell